CardioRenal, a Grenoble, France-based company that specializes in improving treatment at home for patients with severe chronic kidney disease (CKD), raised 3.3M in seed funding.
The backers included French entrepreneurs and longstanding company shareholders (the management).
The company intends to use the funds to pursue its plan to achieve clinical and regulatory approval in preparation for the CE marking of its integrated tool, which is expected in 2023.
Led by Maurice Bérenger, CEO, CardioRenal specializes in improving treatment at home for patients with severe chronic kidney disease (CKD). Its platform that enables doctors to optimize patient treatment through remote monitoring of key blood biomarkers.
CardioRenal completed a clinical trial on the technology in October 2021. The results of this trial will be presented at the European Renal Association congress in Paris, France, in May.
FinSMEs
04/04/2022